Table 1 . Description of long-term cost effectiveness studies characteristics .

Sources/ Authors	Country and year of study	Study population	Intervention	Alternative options for comparison	Outcome measure	Study time horizon
Chen and e.tal	Taiwan /2001	Aged over 30 years	mass screening in 2 and 5 year interval	Over 30 years not screening	life year gained and QALY	Life time
Lee, D. S. et al	USA/ 2000	Wisconsin Medicare population (65 and Older)	Mass screening	No screening	cost saving per diabetic Detected	14 years
Kahn R. and et al	USA/ 2010	Aged 30 years	9 different screening strategies	No screening	QALY	Life time
Schaufler, T. M. and et al	Germany/2010	Aged 35–75	Screening with OGTT	Current status quo (No Screen)	QALY	Life time
Hoerger, T. J. et al	UK/ 2004	Over 35 aged and people with hypertension	Universal and targeted screening	With together and no screening	QALY	Life time
Gillies CL. et al	UK/ 2008	Age 45 at screen time	screening to early detection and treatment for type 2 diabetes, (b) screening for type 2 diabetes and IGT, intervening with lifestyle (c) as for (b) but with pharmacological interventions,	No screening	QALY	50 Years